Table 1 Study characteristics
Author | Years | Number of DES/CABG patients | Number of DM/non-DM patients | Age* (years) | Follow-up (years) | ACS (%) | Coronary artery disease severity | Entry criteria | Stent type | Primary outcome | Adjusting method | Risk of bias |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Randomized controlled trials | ||||||||||||
Morice et al. | 2014 | 346/322 | 150/518 | 65.5 (9.9) | 5 (mean) | 29.8 | Mean SYNTAX score (core-lab): 29.6 DES/30.2 CABG | ≥ 50% ULMCA visual stenosis Silent ischemia or stable/unstable angina | Paclitaxel | Composite of all-cause mortality, stroke, MI, or repeat revascularization at 5-year follow-up | Randomization | Some concern |
Milojevic et al. | 2019 | 948/956 | 554/1350 | 65.9 (9.6) | 3 (mean) | 39.2 | Mean SYNTAX score (core-lab): 26.9 DES/26 CABG | ≥ 70% ULMCA visual stenosis, 50–70% stenosis if significant by invasive or non-invasive testing, SYNTAX ≤ 32 Silent ischemia, angina, or ACS | Everolimus | Composite of all-cause mortality, MI, or stroke at median 3-year follow-up | Randomization | Some concern |
Holm et al. | 2020 | 592/592 | 184/1000 | 66.4 (9.7) | 4.9 (median) | 17.4 | Mean SYNTAX score (core-lab): 22.5 DES/22.4 CABG | ≥ 50% ULMCA visual stenosis or FFR ≤ 0.8 Angina, ACS ≤ 3 additional non-complex lesions | Biolimus | Composite of all-cause mortality, stroke, non-index treatment-related MI or unplanned revascularization at 5 years or until 275 events | Randomization | Some concern |
Park et al. | 2020 | 300/300 | 192/408 | 62.3 (9.8) | 11.3 (median) | 50.5 | Mean SYNTAX score (core-lab): 22.4 DES/25.8 CABG | ≥ 50% ULMCA visual stenosis Silent ischemia, angina, NSTEACS | Sirolimus | Composite of all-cause mortality, MI, stroke, or ischemia-driven revascularization at 10-year follow-up | Randomization | Some concern |
Observational studies | ||||||||||||
Zhao et al. | 2011 | 56/116 | 172/0 | 61 (N/A) | 2.4 (median) | 98.3 | LMCAD + 3-vessel disease: 46.4% DES/73.3% CABG | ULMCAD (severity unspecified) Medically treated DM patients | Sirolimus (94.6%), Zotarolimus (5.4%) | All-cause mortality | Multivariable outcome regression | Serious |
Meliga et al. | 2013 | 520/306 | 826/0 | 66.9 (9.7) | 4.0 (mean) | 66.8 | LMCAD + 3-vessel disease: 38.1% DES/72.9% CABG | ULMCAD (severity unspecified) Medically treated DM patients | Sirolimus (57.9%), Paclitaxel (40.0%), Zotarolimus (0.2%), Everolimus (1.9%) | Composite endpoint of death, myocardial infarction, or stroke | Propensity score with outcome regression | Moderate |
Yu et al. | 2015 | 465/457 | 274/648 | 62.8 (N/A) | 7.1 (median) | 81.0 | LMCAD + 3-vessel disease: 35.3% DES/67.2% CABG | ≥ 50% ULMCA visual stenosis | DES unspecified | Composite endpoint of death, myocardial infarction, or stroke | Multivariable outcome regression | Serious |
Zheng et al. | 2016 | 1442/2604 | 1154/2892 | 61.4 (98) | 3 (mean) | 52.3 | LMCAD + 3-vessel disease: 34.5% DES/78.7% CABG | ≥ 50% ULMCA visual stenosis | DES unspecified | All-cause mortality at 3-years | Propensity score with outcome regression | Moderate |
Lee et al. | 2017 | 950/950 | 736/1164 | 64.6 (9.8) | 4.7 (median) | 58.0 | LMCAD + 3-vessel disease: 60.9% DES/61.4% CABG | ≥ 50% ULMCA visual stenosis | DES unspecified | Composite endpoint of death, myocardial infarction, or stroke | PSM | Moderate |
Lee et al. | 2020 | 804/690 | 507/987 | 62.1 (10.6) | 12 (median) | 72.1 | LMCAD + 3-vessel disease: 34.0% DES/94.1% CABG | ≥ 50% ULMCA visual stenosis | DES unspecified | All-cause mortality | IPTW | Moderate |